Autoimmune diseases — rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, atopic dermatitis — are treated with some of the most expensive drugs in medicine. Biologics like Humira, Dupixent, Skyrizi, Rinvoq, and Enbrel can cost $20,000–$80,000 per year at list price. The 2026 pharmaceutical tariff's impact on this drug class is one of the most consequential questions for patients managing chronic conditions.
The landscape is complex — some drugs are protected by MFN deals, some by biosimilar exemptions, and some face real risk.
Humira — The World's Formerly Bestselling Drug
Humira (adalimumab) from AbbVie occupies a unique position. AbbVie is an Annex III MFN deal company, so the original Humira pays 0% tariff. But the bigger story is biosimilars.
Humira's patents expired, and the FDA has approved over a dozen adalimumab biosimilars, including:
- Hadlima (Samsung Bioepis/Organon)
- Hyrimoz (Sandoz/Novartis)
- Cyltezo (Boehringer Ingelheim — also Annex III)
- Yusimry (Coherus BioSciences)
- Hulio (Mylan/Viatris)
All biosimilars are fully exempt from the tariff — 0% regardless of manufacturer. For most Humira patients, switching to a biosimilar was already financially smart before the tariff. Post-tariff, it becomes even more compelling.
Dupixent (Sanofi) — 0% via MFN Deal
Dupixent (dupilumab) is used for atopic dermatitis, asthma, eosinophilic esophagitis, and nasal polyps. Sanofi — Dupixent's manufacturer — is an Annex III MFN deal company. Dupixent pays 0% tariff effective July 31, 2026. No exposure for Dupixent patients.
AbbVie Drugs — 0% via MFN Deal
AbbVie is Annex III. Their full autoimmune portfolio is covered:
- Skyrizi (risankizumab) — Plaque psoriasis, Crohn's, UC. 0%.
- Rinvoq (upadacitinib) — RA, psoriatic arthritis, UC, AD, AS. 0%.
- Humira — As above, 0%.
Amgen Drugs — 0% via MFN Deal
Amgen is Annex III:
- Enbrel (etanercept) — RA, psoriasis. 0%. Note: Enbrel also has biosimilars (Erelzi, Eticovo) that are also fully exempt.
- Otezla (apremilast) — Psoriasis, psoriatic arthritis. 0%.
Drugs with Real Tariff Risk
Johnson & Johnson (not Annex III):
- Stelara (ustekinumab) — Crohn's, UC, psoriasis. Potential 100% tariff. Note: Stelara biosimilars have been approved (Wezlana, Selarsdi) and are fully exempt.
- Tremfya (guselkumab) — Psoriasis, psoriatic arthritis. Risk.
- Simponi (golimumab) — RA, UC. Risk.
UCB (not Annex III):
- Cimzia (certolizumab) — RA, Crohn's. Risk.
The Biosimilar Strategy for Autoimmune Patients
For patients on drugs with potential tariff exposure — particularly Stelara and Cimzia — checking biosimilar availability is the clearest protective move. Stelara now has multiple approved biosimilars. Ask your rheumatologist or gastroenterologist whether a biosimilar switch is appropriate for your condition.
Use the drug search tool to check your specific autoimmune medication's current tariff classification and whether biosimilar alternatives exist.